NUTRIDOM MELATONIN
- HELPS INCREASE THE TOTAL SLEEP TIME (ASPECT OF SLEEP QUALITY) IN PEOPLE SUFFERING FROM SLEEP RESTRICTION OR ALTERED SLEEP SCHEDULE, E.G. SHIFT-WORK AND JET LAG.
- HELPS TO REDUCE THE TIME IT TAKES TO FALL ASLEEP (SLEEP ONSET LATENCY ASPECT OF SLEEP QUALITY) IN PEOPLE WITH DELAYED SLEEP PHASE SYNDROME.
- HELPS RE-SET THE BODY SLEEP-WAKE CYCLE (ASPECT OF THE CIRCADIAN RHYTHM).
MELATONIN IS USED TO:
HELPS INCREASE THE TOTAL SLEEP TIME (ASPECT OF SLEEP QUALITY) IN PEOPLE SUFFERING FROM SLEEP RESTRICTION OR ALTERED SLEEP SCHEDULE, E.G. SHIFT-WORK AND JET LAG.
HELPS TO PREVENT AND/OR REDUCE THE EFFECTS OF JET LAG (E.G. DAYTIME FATIGUE, SLEEP DISTURBANCE) FOR PEOPLE TRAVELLING BY PLANE EASTERLY ACROSS TWO OR MORE TIME ZONES.
HELPS TO REDUCE THE TIME IT TAKES TO FALL ASLEEP (SLEEP ONSET LATENCY ASPECT OF SLEEP QUALITY) IN PEOPLE WITH DELAYED SLEEP PHASE DISORDER.
HELPS RE-SET THE BODY'S SLEEP-WAKE CYCLE (ASPECT OF THE CIRCADIAN RHYTHM).
CAUTIONS AND WARNINGS
CONSUMPTION WITH ALCOHOL, OTHER MEDICATIONS OR NATURAL HEALTH PRODUCTS WITH SEDATIVE PROPERTIES IS NOT RECOMMENDED.
IF YOU ARE TAKING ONE OF THE FOLLOWING MEDICATIONS, CONSULT A HEALTH CARE PRACTITIONER PRIOR TO USE: ANTICOAGULANT, ANTICONVULSANT, BLOOD PRESSURE MEDICATIONS, IMMUNOSUPPRESSIVE MEDICATIONS, SEDATIVE, HYPNOTIC OR PSYCHOTROPIC MEDICATIONS, OR STEROIDS.
IF YOU HAVE ONE OF THE FOLLOWING CONDITIONS, CONSULT A HEALTH CARE PRACTITIONER PRIOR TO USE: ASTHMA, CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, DEPRESSION, DIABETES OR HYPOGLYCAEMIA, HORMONAL DISORDER, IMMUNE SYSTEM DISEASE, LIVER DISEASE, MIGRAINE, OR SEIZURE DISORDERS.
IF SYMPTOMS PERSIST CONTINUOUSLY FOR MORE THAN 4 WEEKS (CHRONIC INSOMNIA), CONSULT YOUR HEALTH CARE PRACTITIONER.
IF YOU ARE PREGNANT OR BREASTFEEDING, DO NOT USE THIS PRODUCT.
MILD GASTROINTESTINAL SYMPTOMS (NAUSEA, VOMITING, OR CRAMPING) HAVE BEEN KNOWN TO OCCUR IN WHICH CASE, DISCONTINUE USE.
RARE ALLERGIC REACTIONS HAVE BEEN KNOWN TO OCCUR IN WHICH CASE, DISCONTINUE USE.
ANDRADE C, SRIHARI BS, REDDY KP, CHANDRAMMA L. MELATONIN IN MEDICALLY ILL PATIENTS WITH INSOMNIA: A DOUBLE BLIND PLACEBO-CONTROLLED STUDY. JOURNAL OF CLINICAL PSYCHIATRY 2001;62(1):41-5
ARANGINO S, CAGNACCI A, ANGIOLUCCI M, VACCA AMB, LONGU G, VOLPE A, MELIS GB. EFFECTS OF MELATONIN ON VASCULAR REACTIVITY, CATECHOLAMINE LEVELS, AND BLOOD PRESSURE IN HEALTHY MEN. AMERICAN JOURNAL OF CARDIOLOGY 1999; 83(9):1417-1419.
ATTENBURROW ME, COWEN PJ, SHARPLEY AL. LOW DOSE MELATONIN IMPROVES SLEEP IN HEALTHY MIDDLE-AGED SUBJECTS. PSYCHOPHARMACOLOGY (BERLIN) 1996;126(2):179-81
AVERY D, LENZ M, LANDIS C. GUIDELINES FOR PRESCRIBING MELATONIN. ANNALS OF MEDICINE 1998;30(1):122-30
BROWN GM, PANDI-PERUMAL SR, TRAKHT I, CARDINALI DP. MELATONIN AND ITS RELEVANCE TO JET LAG. TRAVEL MEDICINE AND INFECTIOUS DISEASE 2009;7:69-81.
BRUSCO LI, FAINSTEIN I, MARQUEZ M, CARDINALI DP. EFFECT OF MELATONIN IN SELECTED POPULATIONS OF SLEEP-DISTURBED PATIENTS. BIOLOGICAL SIGNALS AND RECEPTORS 1999;8(1-2):126-31
BRZEZINSKI A, VANGEL MG, WURTMAN RJ, NORRIE G, ZHDANOVA I, BEN-SHUSHAN A, FORD I. EFFECTS OF EXOGENOUS MELATONIN ON SLEEP: A META-ANALYSIS. SLEEP MEDICINE REVIEWS 2005;9:41-50
BUSCEMI N, VANDERMEER B, PANDYA R, HOOTON N, TJOSVOLD L, HARTLING L, BAKER G, VOHRA S, KLASSEN T. MELATONIN FOR TREATMENT OF SLEEP DISORDERS. EVIDENCE REPORT/TECHNOLOGY ASSESSMENT NO. 108. AHRQ PUBLICATION NO. 05-E002-2. ROCKVILLE (MD): U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY. NOVEMBER, 2004
CAGNACCI A, ARANGINO S, ANGIOLUCCI M, MELIS GB, FACCHINETTI F, MALMUSI S, VOLPE A. EFFECT OF EXOGENOUS MELATONIN ON VASCULAR REACTIVITY AND NITRIC OXIDE IN POSTMENOPAUSAL WOMEN: ROLE OF HORMONE REPLACEMENT THERAPY. CLINICAL ENDOCRINOLOGY 2001B;54:261-266.
This page is not intended to be a comprehensive review of the medicinal ingredient.
| NPN |
PRODUCT CODE |
POTENCY |
CAPSULE |
| 80033881 |
AAA016 |
3MG MELATONIN |
60 VEGETABLE CAPSULES |
.jpg)
.png)
